News & Updates

ASCL1 a potential therapeutic target for treating Cushing’s disease
ASCL1 a potential therapeutic target for treating Cushing’s disease
20 Aug 2022

A recent study attempting to understand the pathogenesis of Cushing’s disease (CD) suggests the potential of achaete-scute complex homolog 1 (ASCL1), a pioneer transcription factor, as a therapeutic target for the treatment of CD.

ASCL1 a potential therapeutic target for treating Cushing’s disease
20 Aug 2022
Which factors predict relapse after antiviral therapy cessation in paediatric CHB?
Which factors predict relapse after antiviral therapy cessation in paediatric CHB?
19 Aug 2022
Add-on dupilumab reduces OCS use in patients with steroid-dependent severe asthma
Add-on dupilumab reduces OCS use in patients with steroid-dependent severe asthma
19 Aug 2022 byAudrey Abella

In patients with chronic dependence on oral corticosteroids (OCS) for severe asthma, long-term exposure to dupilumab supports sustained reduction in OCS dosage and improvement in clinical outcomes for up to 96 weeks, according to an analysis of the phase III LIBERTY ASTHMA TRAVERSE study.

Add-on dupilumab reduces OCS use in patients with steroid-dependent severe asthma
19 Aug 2022
Probiotics, prebiotics, synbiotics boost metabolism in NAFLD
Probiotics, prebiotics, synbiotics boost metabolism in NAFLD
19 Aug 2022 byTristan Manalac

Patients with nonalcoholic fatty liver disease (NAFLD) who take probiotics, prebiotics, or synbiotics (PPS) may have better energy metabolism, according to a recent study.

Probiotics, prebiotics, synbiotics boost metabolism in NAFLD
19 Aug 2022